VE-465

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 561560

CAS#: 639089-73-9

Description: VE-465 is a novel Aurora kinase inhibitor. The Aurora kinase family of kinases (Aurora A, B, and C) are involved in multiple mitotic events, and aberrant expression of these kinases is associated with tumorigenesis.

Chemical Structure

img
VE-465
CAS# 639089-73-9
Instruction

Theoretical Analysis

MedKoo Cat#: 561560
Name: VE-465
CAS#: 639089-73-9
Chemical Formula: C22H28N8OS
Exact Mass: 452.21
Molecular Weight: 452.580
Elemental Analysis: C, 58.39; H, 6.24; N, 24.76; O, 3.54; S, 7.08

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: VE-465; VE 465; VE465;

IUPAC/Chemical Name: N-[4-[[4-(4-Methyl-1-piperazinyl)-6-[(5-methyl-1H-pyrazol-3-yl)amino]-2-pyrimidinyl]thio]phenyl]-propanamide

InChi Key: LCQYMDMUCJFFKN-UHFFFAOYSA-N

InChi Code: InChI=1S/C22H28N8OS/c1-4-21(31)23-16-5-7-17(8-6-16)32-22-25-18(24-19-13-15(2)27-28-19)14-20(26-22)30-11-9-29(3)10-12-30/h5-8,13-14H,4,9-12H2,1-3H3,(H,23,31)(H2,24,25,26,27,28)

SMILES Code: CCC(NC1=CC=C(SC2=NC(NC3=NNC(C)=C3)=CC(N4CCN(C)CC4)=N2)C=C1)=O

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 452.58 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Falchook GS, Bastida CC, Kurzrock R. Aurora Kinase Inhibitors in Oncology Clinical Trials: Current State of the Progress. Semin Oncol. 2015 Dec;42(6):832-48. doi: 10.1053/j.seminoncol.2015.09.022. Epub 2015 Sep 24. Review. PubMed PMID: 26615129.

2: Cooper S, Giles FJ, Savona MR. Overcoming resistance in chronic myelogenous leukemia. Leuk Lymphoma. 2009 Nov;50(11):1785-93. doi: 10.3109/10428190903267559. Review. PubMed PMID: 19883308.

3: Liang YQ, Chen BA, Chen YL. [Research progress on aurora kinase inhibitor MK-0457 in therapy for some hematological malignancies -- review]. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2009 Jun;17(3):810-5. Review. Chinese. PubMed PMID: 19549414.

4: Chen XG, Zhang Y. [Recent advance in the study of novel anti-tumor targets and drugs--aurora kinase and Pin1]. Yao Xue Xue Bao. 2009 Mar;44(3):264-9. Review. Chinese. PubMed PMID: 19449522.

5: Hasselbalch HC, Birgens H, Dufva IH, Dalseg AM, Brown Pde N, Jensen MK, Vangsted A. [Novel medical treatment modalities in hematology]. Ugeskr Laeger. 2008 Jun 9;170(24):2115-9. Review. Danish. PubMed PMID: 18565291.

6: Li SA, Lam LK, Ahmed N, Hontz AE, Li JJ. Estrogen-induced breast oncogenesis: modulation by an Aurora kinase inhibitor. Adv Exp Med Biol. 2008;617:213-20. doi: 10.1007/978-0-387-69080-3_20. Review. PubMed PMID: 18497045.

7: Thomas X. [Acute lymphoblastic leukemia with Philadelphia chromosome: treatment with kinase inhibitors]. Bull Cancer. 2007 Oct;94(10):871-80. Review. French. PubMed PMID: 17964981.

8: Kimura S. [Novel anti-CML agents beyond imatinib]. Rinsho Ketsueki. 2007 Jun;48(6):475-84. Review. Japanese. PubMed PMID: 17633095.

9: Doggrell SA. Dawn of Aurora kinase inhibitors as anticancer drugs. Expert Opin Investig Drugs. 2004 Sep;13(9):1199-201. Review. PubMed PMID: 15330750.